E. J. Small

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

T. Choueiri, M. Michaelson, M. Morris, 2019, The oncologist.

Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.

E. Small, D. Petrylak, E. Crawford, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)

K. Owzar, M. Ratain, S. Halabi, 2024, The pharmacogenomics journal.

NCCN Prostate Cancer , Version 2 . 2014 Clinical Practice Guidelines in Oncology

A. D'Amico, P. Kantoff, J. Eastham, 2014 .

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

P. Kantoff, S. Larson, H. Scher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.

T. Choueiri, T. Olencki, D. Feldman, 2018 .